Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Who Are The Key Players In The Exondys 51 Market? The industry landscape comprises key businesses such as Sarepta Therapeutics. These leading players are making strides in growing the exondys 51 ...

Who Are The Key Players In The Exondys 51 Market? The industry landscape comprises key businesses such as Sarepta Therapeutics. These leading players are making strides in growing the exondys 51 ...

For example, Sarepta has yet to complete its confirmatory trial for Exondys, which was approved in 2016. Last year, the FDA granted an accelerated approval to Sarepta’s gene therapy Elevydis ...

and the Duchenne muscular dystrophy treatment eteplirsen (Exondys 51). Two of these drugs are no longer on the market. In 2023, the FDA withdrew its approval of HPC after a years-long battle.

Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise ...